Introduction {#Sec1}
============

Acute radiation oesophagitis (ARO) is a common toxicity associated with thoracic radiotherapy (RT) when the treated volume includes the mediastinum. The incidence and severity of the resulting dysphagia is related to the dose and volume of oesophagus treated \[[@CR1], [@CR2]\]. In patients receiving treatment for lung cancer with curative intent, the administration of concurrent chemotherapy has been shown to improve survival compared with sequential administration \[[@CR3]\]. However, concurrent treatment is also associated with increased oesophageal toxicity. This may be the result of a direct radiosensitising effect of the chemotherapy, or it could be an indirect effect of chemotherapy induced neutropenia which results in impaired healing of the oesophageal epithelium. In support of this latter hypothesis, de Ruysscher et al. observed a significant association between the maximal grade of neutropenia and severity of ARO during chemoradiotherapy (CRT) for NSCLC \[[@CR4]\].

The primary aim of this retrospective analysis was to assess the rates of acute oesophagitis in a cohort of patients treated at our centre, with a particular focus on dosimetric and haematologic risk factors, to independently verify the findings of de Ruysscher et al.

Materials and method {#Sec2}
====================

Approval was granted by the Peter MacCallum Cancer Centre Institutional Ethics committee to conduct this retrospective study. Criteria for inclusion of patient data in the study included a pathological confirmation of NSCLC and treatment with concurrent chemotherapy and radical or high dose palliative radiotherapy at the Peter MacCallum Cancer Centre (East Melbourne campus). Exclusion criteria included previous thoracic RT, inconsistent radiation dose per fraction and hyper-fractionated radiation schedules. We also excluded patients with RT treatment interruptions ≥ 5 days, as mucosal recovery during the break may have confounded interpretation of the relationship between the oesophageal dose volume metrics and grade of oesophagitis.

Patient characteristics, treatment and toxicity data were extracted from paper and electronic medical records. Clinical data included the use of nasogastric (NG) or percutaneous endoscopic gastrostomy (PEG) tube, systemic steroids, proton pump inhibitors (PPI) and H2 receptor antagonists prior to or during treatment. Patients' weight loss, smoking status, presence of auto-immune disease, diabetes and/or reflux, and use of analgesia were recorded. Treatment data included total radiation dose, dose per fraction, overall treatment time and chemotherapy schedules. The presence and grade of acute and late oesophagitis, skin toxicity and neutropenia were assessed in accordance with Common Toxicity Criteria for Adverse Events (CTCAE v3.0). Acute toxicities were defined from the first day of treatment to day 90 and late toxicities were defined from day 91 after the start of RT. Toxicity assessments were undertaken by a radiation oncologist at weekly intervals and by a nurse at additional time-points. During treatment neutropenia data were obtained from pre-chemotherapy blood monitoring. The timing of treatment reviews and blood tests varied between patients.

Three-dimensional conformal RT planning was performed on Xio (Computerized Medical Systems CMS, St Louis, MO, USA), using a fast superposition algorithm and delivered with 6MV photons. Planning was performed in accordance with ICRU guidelines, including dose homogeneity within the planning target volume (PTV) of +7 %/-5 % of the prescribed dose. The outer muscular border of the oesophagus was delineated from the cricoid (superior border) to the gastro-oesophageal junction (inferior border) on CT derived images, using soft-tissue window/level settings. Anatomical and dosimetric endpoints included the absolute length (cm) and volume (cm^3^) of oesophagus, maximum (Dmax) and mean (Dmean) oesophageal doses and percentage volume of oesophagus receiving 20 to 60 Gy (Vx, in 5 Gy increments). The percentage length of oesophagus receiving 20 to 60 Gy (in 10 Gy increments) was recorded for dose encompassing the whole oesophageal circumference (LWO) and the partial oesophageal circumference (LPO).

The rate of ARO was described as the percentage of patients in the study who had experienced ARO of at least grade 1. The rate of late oesophagitis and the rate of high grade ARO (grade 3 or 4) were reported in the same manner. All percentages of oesophagitis were reported together with a 95 % confidence interval (95 % CI) based on the binomial distribution. Assessment of potential prognostic factors with respect to ARO was done using Wilcoxon rank sum test and Spearman's correlation. ARO, acute neutropenia and acute skin reaction were dichotomised as low grade (0 + 1) vs. high grade (2 + 3 + 4). The association of ARO with acute neutropenia and acute skin reaction was examined using Barnard's test. All *p*-values are 2-sided without adjustment for multiplicity. All statistical analyses were performed in R (R Development Core Team (2012). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL [http://www.R-project.org/](http://www.r-project.org/)).

Results {#Sec3}
=======

Eighty four patients met the eligibility criteria for inclusion in this study. The archived radiotherapy planning data of 30 patients were irretrievable; therefore these patients were excluded from the analysis. Characteristics of the remaining 54 patients are presented in Table [1](#Tab1){ref-type="table"}.Table 1Patient characteristics and clinical factorsVariableCategoryCount%GenderFemale1425.9Male4074.1T Stage147.422240.731324.141324.1X23.7N Stage01324.11814.822648.13611.1X11.9M Stage04685.2159.3X35.6SmokingCurrent smoker916.7Ex-smoker (\<6 months)1018.5Ex-smoker (\> =6 months)3259.3Never smoked35.6Autoimmune diseaseNo5296.3Yes23.7DiabetesNo4685.2Yes814.8Reflux oesophagitisNo4277.8Yes1222.2

Table [2](#Tab2){ref-type="table"} shows the treatment details for CRT and any prescribed other therapies including steroids and analgesia. 42 (78 %) patients received CRT with a radical dose of 60 Gy. The remaining 12 (22 %) patients received high palliative doses ranging between 30 and 50 Gy, details of which have been published previously \[[@CR5]\]. No patient experienced a treatment break. The median change in weight from the start to the end of RT was -1Kg, ranging from −8.5Kg to 3.5Kg.Table 2Treatment detailsVariableCategoryCount%RT dose received\<60Gy1222.260Gy4277.8RT typeHigh dose palliative1018.5Radical4481.5RT breaksNo54100Yes00Chemo regimenCarboplatin + paclitaxel + gefitinib47.4Carboplatin + paclitaxel weekly2037Carboplatin weekly35.6Carboplatin weeks 1 and 61731.5Gemcitabine weekly814.8Vinorelbine + Cisplatin weekly23.7Neoadjuvant chemoNo5296.3Yes^a^23.7NGPEG pre CRTNo54100Yes00NGPEG during CRTNo5398.1Yes11.9Steroids pretreatmentNo4990.7Yes59.3Steroids duringNo2750Yes2750PPI preNo4583.3Yes916.7PPI duringNo3463Yes2037H2Antag pre CRTNo5296.3Yes23.7H2Antag during CRTNo4685.2Yes814.8Local analgesiaNo1731.5Yes3768.5Type local analgesiaAluminium hydroxide and oxethazaine (Mucaine)1232.4Lignocaine viscous and Mucaine2259.5Lignocaine viscous only38.1Systemic analgesiaNo1833.3Yes3666.7Type sys analgesianon-opioid822.2strong opioid2158.3weak opioid719.4^a^Of the 2 patients who received neoadjuvant chemotherapy, 1 received Carboplatin + Paclitaxel weekly and 1 received Carboplatin + Gemcitabine*NGPEG* Nasogastric tube or PEG*PPI* proton pump inhibitor*H2antag* Histamine H2 receptor antagonist

The incidence and grade of acute and late oesophageal toxicities are presented in Table [3](#Tab3){ref-type="table"}. Of the 54 patients included in the trial, 48 (89 %) had ARO of at least grade 1 (95 % CI: 78 % to 95 %) and 5 (9 %) patients had late oesophagitis of at least grade 1 (95 % CI: 4 % to 20 %). Of the 29 patients with ARO grade ≤ 1, 5 (17 %) experienced high grade acute neutropenia (grade ≥ 2). In contrast, of the 25 patients with high grade ARO, 11 (44 %) experienced high grade acute neutropenia (*p* = 0.035). The maximum grade of oesophagitis was not significantly associated with the maximum grade of acute skin reaction (*p* = 0.529). There was not a statistically significant association between grade of ARO and sex (*p* = 0.722) or dose, when dichotomised to \<60 Gy and 60 Gy (*p* = 0.401).Table 3Description of toxicitiesVariableCategoryCount% \[95 % CI\]Grade of acute oesophagitis0611.1 \[5.2 - 22.2\]12342.6 \[30.3 - 55.8\]21731.5 \[20.7 - 44.7\]3814.8 \[7.7 - 26.6\]Late oesophagitis recordedNo2546.3 \[33.7 - 59.4\]Yes2953.7 \[40.6 - 66.3\]Grade of late oesophagitis02482.8 \[65.5 - 92.4\]126.9 \[1.9 - 22.0\]2310.3 \[3.6 - 26.4\]Reason no late oesophagitisDisease progression625.0 \[12.0 - 44.9\]New second primary14.2 \[0.2 - 20.2\]Not documented in clinical record937.5 \[21.2 - 57.3\]Patient died before first assessment312.5 \[4.3 - 31.0\]Patient had surgery14.2 \[0.2 - 20.2\]Patient lost to F/U416.7 \[6.7 - 35.9\]

The mean (SD) oesophageal length was 22.4 cm (2.2) and oesophageal volume was 86.9 cm^3^ (16.6). The mean (SD) RT field length was 14.2 cm (3.9). Table [4](#Tab4){ref-type="table"} illustrates details of the RT dosimetric data and the association of oesophageal dose with ARO grade for all patients and the subset of patients where the oesophagus received the pre-specified dosimetric endpoint. For all patients, the mean (SD) oesophageal Dmax was 50.2 Gy (18) and the mean (SD) oesophageal Dmean was 20.8 Gy (10.8).Table 4Radiation therapy dosimetric data and the relationship of oesophageal dose with grade of acute oesophagitisAll patients (*n* = 54)Only patients receiving pre-specified dose to the oesophagusVariableMeansdSpearman correlation*p*-value*n*Spearman correlation*p*-valueDmax (Gy)50.218.00.1430.302\-\--Dmean (Gy)20.810.80.269**0.049**\-\--VO2043.923.10.306**0.024**510.355**0.011**VO2540.822.10.297**0.029**500.303**0.033**VO3034.8230.2380.083490.2690.062VO3530.824.40.2010.146430.337**0.027**VO4026.923.90.1620.243410.3020.055VO4523.8230.1630.24380.3100.058VO5021.121.10.1520.273380.2890.078VO5517.119.10.1240.371370.2900.081VO606.910.90.1040.455250.591**0.002**LPO2048.9210.2050.136510.2400.090LPO3042.221.40.1340.336500.1070.458LPO4034.224.70.1060.448410.2060.196LPO5029.9240.1010.469380.1890.255LPO6012.516.10.0480.728270.428**0.026**LWO2029.822.70.319**0.019**430.1850.236LWO3020.520.40.2500.068360.1480.389LWO4014.418.60.2310.093300.2480.186LWO508.614.10.2100.128200.2140.364LWO6013.80.1390.31660.1470.781*VOx* Percentage volume of oesophagus receiving x dose (%), *LPOx* Percentage length of partial oesophagus receiving x dose (%), *LWOx* Percentage length of whole oesophagus receiving x dose (%). Values in bold type indicate statistical significance, *p* \< 0.05

When analysing the association between ARO grade and Vx parameters, there was a statistically significant correlation between the grade of ARO and percentage of oesophagus treated at 20 Gy for the whole patient cohort (*n* = 54, r~s~ = 0.306, *p* = 0.024) and the subset of patients with oesophagus volumes treated to 20 Gy (*n* = 51, r~s~ = 0.355, *p* = 0.011). The correlation between the grade of ARO and percentage of oesophagus treated at 60 Gy was not statistically significant for the whole cohort (*n* = 54, r~s~ = 0.104, *p* = 0.455) but highly significant for the subset of patients receiving 60 Gy to the oesophagus (*n* = 25, r~s~ = 0.591, *p* = 0.002). As shown in Table [4](#Tab4){ref-type="table"}, the percentage of oesophagus receiving at least 25 Gy (*n* = 50, r~s~ = 0.303, *p* = 0.033), 35 Gy (*n* = 43, r~s~ = 0.337, *p* = 0.027) were also statistically significant in the subset of patients receiving 25 Gy and 35 Gy to the oesophagus, respectively.

The analysis of association between ARO grade and irradiated length showed a statistically significant correlation in patients receiving 60 Gy to the partial oesophageal circumference (*n* = 27, r = 0.428, *p* = 0.026) but not in patients where the whole oesophageal circumference was irradiated to 60 Gy (*n* = 6, r = 0.147, *p* = 0.781). For the whole patient cohort, only the whole oesophageal circumference treated to 20 Gy was statistically significantly associated with acute oesophagitis grade (r = 0.319, *p* = 0.019). Fig. [1](#Fig1){ref-type="fig"} and Fig. [2](#Fig2){ref-type="fig"} illustrate the relationship of grade of acute oesophagitis with volume and length receiving 20 Gy, respectively.Fig. 1Box-and-whisker plot showing the percentage of oesophagus volume treated at 20Gy according to grade of acute oesophagitisFig. 2Box-and-whisker plot showing the percentage of oesophagus length treated at 20Gy (whole circumference) according to grade of acute oesophagitis

The relationship of neutropenia and oesophagitis was assessed on all patients and also separately in the subsets of patients with \>50 % of oesophagus volume receiving 20Gy and ≤50 % of oesophagus volume receiving 20Gy and the results presented in Table [5](#Tab5){ref-type="table"}. Higher grades of neutropenia were associated with higher grades of oesophagitis when assessed in the whole cohort. Despite not achieving statistical significance, the results from both volume subsets were consistent with the result for the whole cohort, probably a reflection of the small number of patients in the subsets. If however the relationship between oesophagitis and neutropenia is tested adjusting for percentage of oesophagus volume receiving 20Gy (as a continuous variable), neutropenia was associated with oesophagitis (OR = 3.82 95 % CI \[1.06 -- 15.79\], *p* = 0.048).Table 5Grade of oesophagitis and grade of neutropenia according to percentage of oesophagus receiving 20 Gy% of oesophagus volume receiving 20GyAcute neutropenia gradeAcute oesophagitis grade*p*-value0 + 12 + 3 + 450 % or less0 + 117 (85 %)6 (55 %)0.0712 + 3 + 43 (15 %)5 (45 %)\>50 %0 + 17 (78 %)8 (57 %)0.4002 + 3 + 42 (22 %)6 (43 %)Overall0 + 124 (83 %)14 (56 %)0.0352 + 3 + 45 (17 %)11 (44 %)

Discussion {#Sec4}
==========

ARO is a common, painful and debilitating toxicity associated with high dose CRT for locally advanced NSCLC, and mitigation of the risk of high grade ARO should be a priority of thoracic radiation oncology research. Oesophageal dose and volume are well recognised risk factors \[[@CR1], [@CR2]\], and our data are consistent with the literature in this regard. All of our patients received concurrent chemotherapy, also a recognised risk factor, although it is not known whether as a result of direct radiosensitisation of the oesophageal mucosa, or indirectly through chemotherapy induced neutropenia, or a combination of both. We have shown a significant association between grade of ARO and grade of neutropenia, supporting the previous findings of de Ruysscher et al. in favour of an indirect effect \[[@CR4]\]. The implications are that existing models predicting severity of ARO based purely on oesophageal dose volume metrics \[[@CR1]\] are oversimplified and may need refinement by adjustment for the effect of neutropenia.

It is not surprising that there should be a relationship between grade of ARO and neutropenia. Chemotherapy and RT are known to reduce the integrity of the oesophageal mucosal epithelium, thereby damaging the first line of defence against pathogens \[[@CR6]\]. Healing of the mucosa will be delayed if the inflammatory response is impaired due to a lack of neutrophils. Indeed, prophylactic G-CSF has been investigated for its ability to reduce mucositis in patients having radiotherapy for head and neck cancer. In one randomised trial, G-CSF was associated with a non-significant reduction in mucositis, but also a reduction in local cancer control \[[@CR7]\].

In de Ruysscher's study, neutropenia was only observed in patients who received CRT and it was the most significant parameter for predicting ARO \[[@CR4]\]. Although our patient numbers were limited, they are consistent with the findings of de Ruysscher et al. and we are not aware of any other reports implicating neutropenia as a contributory factor to the grade of ARO.

Several dosimetric endpoints in our study were statistically associated with ARO. These included the mean oesophageal dose (*p* = 0.049), consistent with some previous studies \[[@CR1]\]. Low doses to large oesophageal volumes were statistically significantly associated with high oesophageal toxicity in our cohort of patients receiving CRT, including the volume receiving 20Gy (*p* = 0.026) and whole oesophageal circumference receiving 20Gy (*p* = 0.019). In the subset analysis of patients treated to given doses, the oesophagus V60 was also associated with oesophagitis (r~s~ = 0.591, *p* = 0.002). Although this finding represents a small subset of 25 patients, it is consistent with other literature, including Bradley et al., who reported the association between oesophagitis and V60 in a study of 166 patients \[[@CR8]\]. Similar to our own findings, Takeda et al. \[[@CR9]\] and Belderbos et al. \[[@CR10]\] concluded that the most significant dosimetric parameter was the volume of oesophagus receiving at least 35Gy (*p* \< 0.001). These data were based on the incidence of ≥ Grade 2 oesophagitis, whereas our own data are for ≥ Grade 1 toxicity.

The proximity of primary lung cancers and mediastinal nodes to the oesophagus in many CRT candidates means that inclusion of the oesophagus within the treated volume is often unavoidable, even with IMRT techniques. The opportunities for reducing oesophageal dose and volume are therefore limited. Our results suggest that an alternative strategy worth investigating may be the use of concurrent chemotherapy regimens which are less likely to cause myelosuppression but without loss of therapeutic benefit.

Conclusions {#Sec5}
===========

This study suggests that in patients receiving concurrent chemoradiotherapy for NSCLC risk factors for radiation oesophagitis include not only oesophageal dose and volume, but also neutropenia. The determination of oesophageal dose volume constraints may not be reliable unless this is taken into account. It may be possible to reduce the risk of high grade oesophagitis by choosing a concurrent chemoradiotherapy regimen with a low likelihood of myelosuppression.
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